Papillary Thyroid Carcinomas with Tall Cell Features: An Intermediate Entity Between Classic and Tall Cell Subtypes
Main finding · Negative composite outcome (death, progression or need for advanced therapy)Result — go to the resultHazard ratio 4.3 CI 1.1–16.1Authors' conclusion
Our study demonstrates a continuum of disease-specific risk of PTC, pointing at PTCtcf as an intermediate entity between tcPTC and classic PTC.
Study context
- Population
- Consecutive patients with tcPTC and PTCtcf evaluated at a tertiary academic referral center 2005–2020, plus a comparative cohort of classic PTC
- Participants
- 292 patients
- Exposure
- tcPTC vs PTCtcf vs classic PTC
- tcPTCn = 81
- PTCtcfn = 65
- Classic PTCn = 146reference
- Outcome
- Negative composite outcome:
- Death
- Progression
- Need for advanced therapy
Methodological detailsobservational, single tertiary academic referral centre, consecutive patients, targeted next-generation sequencing in a subset
- Observational
- Single tertiary academic referral centre
- Consecutive patients
- Targeted next-generation sequencing in a subset
Main finding
As reported in the abstract
Hazard ratio
4.3
CI 1.1–16.1
P = 0.03
By group
tcPTCvs Classic PTC
HR 4.3 (CI 1.1–16.1); P = 0.03
Observational data: associations, not effects.
Further findings
5-year PFS
Advanced AJCC stage — between tcPTC and PTCtcf · comparison across the three groups
P = 0.002
Macroscopic extrathyroidal extension — between tcPTC and PTCtcf · comparison across the three groups
P < 0.001
| Outcome | tcPTC | PTCtcf | Classic PTC | P value |
|---|---|---|---|---|
| Hotspot TERT promoter mutations (sequenced subset)tcPTC vs PTCtcf · more with tcPTC | 44% | 6% | — not stated in the abstract | P = 0.012 |
— not stated in the abstract
Original publication
Papillary Thyroid Carcinomas with Tall Cell Features: An Intermediate Entity Between Classic and Tall Cell Subtypes. Thyroid. Published 25 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →